Dupilumab for Eosinophilic Esophagitis With Severe Strictures
Dupilumab for Eosinophilic Esophagitis With Severe Strictures
Active, not recruiting · NCT06352073 · Registry updated 2026-04-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dupilumab for Eosinophilic Esophagitis With Severe Strictures | Constriction, Pathologic, Digestive System Diseases, Eosinophilia, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, digestive system disorder, eosinophilic esophagitis, esophageal disorder, esophagitis, gastroenteritis, hematologic disorder, immune system disorder, leukocyte disorder | Active, not recruiting | Phase 4 | 2026-04-29 | NCT06352073 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Regeneron Pharmaceuticals | 238 |
| Sanofi | 254 |
| University of North Carolina, Chapel Hill | 249 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of North Carolina at Chapel Hill | Chapel Hill | United States | 129 |